New hemophilia remedy offers potential for fewer injections

(HealthDay)—Eloctate, Antihemophilic Factor Fc Fusion has been approved by the U.S. Food and Drug Administration for people with Hemophilia A. It's designed to require less frequent injections than standard therapies used to reduce the frequency of bleeding episodes in people with the disorder, the FDA said in a news release.

Hemophilia A is an inherited that affects mostly males. Caused by a defective Factor VIII gene, it affects about 1 in 5,000 males in the United States. People with the disorder are prone to serious bleeding episodes, primarily affecting the joints.

Eloctate's safety and effectiveness were evaluated in a clinical study of 164 people. No safety concerns were identified in the trial, the FDA said.

The product is produced by Biogen Idec, based in Cambridge, Mass.

More information: The FDA has more about this approval.

add to favorites email to friend print save as pdf

Related Stories

FDA approves rixubis for prophylactic tx in hemophilia B

Jun 28, 2013

(HealthDay)—Rixubis (coagulation factor IX recombinant) has been approved by the U.S. Food and Drug Administration to prevent routine bleeding episodes in people aged 16 and older with hemophilia B, the agency said in a ...

Tretten approved for genetic clotting disorder

Dec 23, 2013

(HealthDay)—Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.

New gene therapy targets hemophilia

Dec 11, 2013

Researchers at the UNC School of Medicine and the Medical College of Wisconsin found that a new kind of gene therapy led to a dramatic decline in bleeding events in dogs with naturally occurring hemophilia ...

Recommended for you

FDA to start regulating lab-developed tests

13 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments